All In Biotech

Drug Trial Radar · NCT05118789

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors (ARROS-1)

Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

359

Planned (sponsor's estimate)

Start

Jan 4, 2022

Primary completion

Dec 31, 2027

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Nuvalent Inc.Industry
Sponsor type
Industry
First posted
Nov 12, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 1/2, dose escalation and expansion study designed to evaluate the safety and tolerability of zidesamtinib (NVL-520), determine the recommended phase 2 dose (RP2D), and evaluate the antitumor activity in patients with advanced ROS1-positive (ROS1+) NSCLC and other advanced ROS1-positive solid tumors. Phase 1 will determine the RP2D and, if applicable, the maximum tolerated dose (MTD) of zidesamtinib in patients with advanced ROS1-positive solid tumors. Phase 2 will determine the objective response rate (ORR) as assessed by Blinded Independent Central Review (BICR) of zidesamtinib at the RP2D. Secondary objectives will include the duration of response (DOR), time to response (TTR), progression-free survival (PFS), overall survival (OS), and clinical benefit rate (CBR) of zidesamtinib in patients with advanced ROS1-positive NSCLC and other solid tumors.

Conditions

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Interventions

  • Zidesamtinib (NVL-520)Drug

    Oral tablet of zidesamtinib (NVL-520)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) (Phase 1)Time frame: Within 28 days of last patient dosed during dose escalation
  2. Recommended Phase 2 Dose (RP2D)Time frame: Within 28 days of last patient dosed during dose escalation.
  3. Objective Response Rate (ORR) (Phase 2)Time frame: 2-3 years after first patient dosed.

Locations

63 sites in 14 countries. Site status is shown where the registry gives one.

  • UCI Medical Center

    Orange, California · Recruiting

  • Stanford Medicine

    Palo Alto, California · Recruiting

  • UC Davis Comprehensive Cancer Center

    Sacramento, California · Recruiting

  • University of Colorado Cancer Center

    Denver, Colorado · Recruiting

  • Georgetown University Medical Center

    Washington D.C., District of Columbia · Recruiting

  • University of Miami

    Coral Gables, Florida · Recruiting

  • University of Chicago

    Chicago, Illinois · Recruiting

  • Mass General Hospital

    Boston, Massachusetts · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Cancer Institute

    Detroit, Michigan · Recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center

    New York, New York · Recruiting

  • Atrium Health Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Ohio State University

    Columbus, Ohio · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Sarah Cannon Research Institute

    Nashville, Tennessee · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Active not recruiting

  • NEXT Oncology - Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • University of Washington / Fred Hutchinson Cancer Center

    Seattle, Washington · Recruiting

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia · Recruiting

  • Peter MacCallum Cancer Centre

    Melbourne, Victoria, Australia · Recruiting

  • University Hospital Leuven

    Leuven, Belgium · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • Princess Margaret Cancer Research

    Toronto, Ontario, Canada · Recruiting

  • Centre Legon Berard

    Lyon, France · Recruiting

  • CHU de Nantes

    Nantes, France · Recruiting

  • Claudius Regaud Institute

    Toulouse, France · Recruiting

  • Institute Gustave Roussy

    Villejuif, France · Recruiting

  • Cologne University Hospital

    Cologne, Germany · Recruiting

  • Università Politecnica Marche

    Ancona, Italy · Recruiting

  • IRCCS Istituto Tumori Giovanni Paolo II

    Bari, Italy · Completed

  • Istituto Europeo di Oncologia

    Milan, Italy · Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Italy · Recruiting

  • Istituto Oncologico Veneto

    Padova, Italy · Recruiting

  • Ospedale Santa Maria delle Croci

    Ravenna, Italy · Recruiting

  • Istituto Nazionale Tumori Regina Elena

    Rome, Italy · Recruiting

  • Kanagawa Cancer Center

    Kanagawa, Japan · Recruiting

  • Okayama University Hospital

    Okayama, Japan · Recruiting

  • Kindai University Hospital

    Osaka, Japan · Recruiting

Showing 40 of 63 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.